retatrutide approval fda 2025 Letter regarding PolitiFact | A patient got

Is Ozempic Safe for Long-Term Weight Loss Management

The FDA has distinguished between mass-marketed compounded products and patient-specific compounding performed under Section 503A of the FD&C Act, which may remain permissible in narrow circumstances where a patient's medical needs cannot be met by an FDA-approved drug

Tirzepatide, on the other hand, offers dual action on GLP-1 and GIP receptors, making it a preferred choice for patients seeking significant blood sugar reduction and weight loss, though it may carry a higher risk of gastrointestinal side effects

Feeling good about themselves was reported by 32, and 25 said they were happier day to day

Patient-specific factors that may increase risk include recent dose escalation, higher doses, significant gastrointestinal symptoms, diabetes-related gastroparesis, and autonomic neuropathy